Intellectual Property

TVAX® holds a comprehensive intellectual property position broadly protecting its proprietary immunotherapy platform.  Patents issued in the United States, Europe and Canada cover various key processes that comprise the company’s complete treatment platform.  Furthermore, the nature of the TVAX technology makes it extremely difficult, if not impossible, to mimic in generic form, which we believe may protect it from competition long after expiration of the company’s strong intellectual property and orphan product protection.